Related Experiment Video
Updated: Apr 4, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
Risk Factors of the Invasive Breast Cancer Locoregional Recurrence.
R V Liubota1, A S Zotov1, R I Vereshchako1
1Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
Biomed Research International
|September 5, 2015
Summary
Breast cancer recurrence is higher in premenopausal women and those with Her/2neu overexpression. Locoregional recurrence significantly impacts survival rates, underscoring the importance of tailored treatment strategies.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Research
Background:
- Investigating locoregional breast cancer recurrence rates.
- Analyzing recurrence-free survival and overall survival.
- Examining the impact of surgical scope, menstrual status, and tumor characteristics on outcomes.
Purpose of the Study:
- To estimate the frequency of locoregional breast cancer recurrence.
- To determine recurrence-free survival periods.
- To assess 3- and 5-year survival rates based on various patient and tumor factors.
Main Methods:
- Comparative analysis of 218 breast cancer patients: 99 undergoing breast-conserving surgery (BCS) and 119 radical mastectomy (RME).
- All patients had regional lymph node dissection.
- Prognostic factors assessed included tumor size, differentiation, lymph node metastasis, ER, PR, and Her/2neu expression.
Main Results:
- Locoregional recurrence observed in 13% of BCS patients versus 9% of RME patients.
- Recurrence-free periods were 53 ± 8 months (BCS) and 56 ± 10 months (RME).
- Higher recurrence rates noted in premenopausal women and those with Her/2neu hyperexpression.
Conclusions:
- Premenopausal status and Her/2neu hyperexpression are associated with increased locoregional recurrence risk.
- Locoregional recurrence negatively impacts survival, reducing 3-year survival by 7.1% and 5-year survival by 20.3%.
